Integra LifeSciences (IART) Projected to Post Earnings on Wednesday

Integra LifeSciences (NASDAQ:IART) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect Integra LifeSciences to announce earnings of $0.48 per share and revenue of $417.6170 million for the quarter. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Investors may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The business had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. During the same quarter in the prior year, the firm earned $0.41 earnings per share. The firm’s revenue was up 2.4% on a year-over-year basis. On average, analysts expect Integra LifeSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Integra LifeSciences Trading Down 1.3%

Shares of IART stock opened at $19.53 on Tuesday. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. The business has a 50-day moving average price of $17.50 and a two-hundred day moving average price of $13.36. Integra LifeSciences has a 12-month low of $8.70 and a 12-month high of $20.40. The firm has a market cap of $1.52 billion, a P/E ratio of -3.02, a price-to-earnings-growth ratio of 1.37 and a beta of 1.22.

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors have recently bought and sold shares of the stock. Rubric Capital Management LP grew its position in Integra LifeSciences by 1.3% during the 4th quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock worth $96,304,000 after acquiring an additional 100,000 shares during the last quarter. Invesco Ltd. lifted its position in Integra LifeSciences by 0.9% in the fourth quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock valued at $43,754,000 after purchasing an additional 31,931 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Integra LifeSciences by 9.2% during the third quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after purchasing an additional 267,134 shares during the period. State Street Corp grew its holdings in shares of Integra LifeSciences by 0.8% in the fourth quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock worth $34,933,000 after purchasing an additional 21,717 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY grew its holdings in shares of Integra LifeSciences by 5.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 2,664,998 shares of the life sciences company’s stock worth $33,099,000 after purchasing an additional 135,198 shares during the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IART has been the topic of a number of research reports. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Wells Fargo & Company upped their target price on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Wall Street Zen cut shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Truist Financial lifted their price target on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Finally, Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $18.33.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.